Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study

October 10, 2006 updated by: University of Turin, Italy
The aim of the present study was to evaluate whether an in vivo treatment with an antioxidant vitamin (vitamin C) might substantially affect serum levels of resistin, a recently described adipokine, whose clinical significance is still controversial in humans.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

INTRODUCTION

Background

Resistin, a recently described adipokine, belonging to the cysteine-rich secretory protein family, was originally described as an adipocyte-derived polypeptide, that provides the link between obesity and insulin resistance in mice1-2. However, resistin is expressed at very low concentrations in human adipose cells, whereas at high levels in mononuclear leukocytes, macrophages, spleen, bone marrow cells. The striking differences in the genomic organization and cellular source of resistin in rodents make the biological effects found in the mouse not readily transferable to humans3-5. Accordingly, an increasing number of reports raised doubts regarding the possibility of an important relationship between human resistin and various metabolic disturbances, characteristic of obesity and type 2 diabetes4-5. Resistin was originally found to be related to proteins induced during lung inflammation6, and the high expression levels of resistin in leukocytes, the associations between this protein and inflammatory markers, the property to stimulate in vivo inflammatory cytokines suggest the possibility that resistin may be involved in the inflammation process6.

Data supporting the participation of resistin in oxidative processes have been sporadically published. A significant interaction among a single nucleotide polymorphism in the promoter of the human resistin gene and a marker of oxidative stress (NAD(P)H:quinone oxidoreductase I) has been found7. Retinoic acid, the acid form of vitamin A, inhibited the expression of resistin in mice and reduced the higher resistin levels of ten males affected by psoriasis8. Resistin serum levels were inversely associated with nitrotyrosine (NT), a product of free radical activity9.

A pilot-analysis performed in five healthy volunteers showed that oral administration of vitamin C for 15 days determined a slight reduction in resistin serum levels.

Aim

The aim of the present study was to evaluate whether an in vivo treatment with an antioxidant vitamin (vitamin C) might substantially affect resistin serum levels. For this purpose, serum resistin values were evaluated in a group of healthy subjects, randomized to receive orally 2 g ascorbic acid for two weeks. Values of fasting glucose, insulin, total and HDL-cholesterol, triglycerides, C-reactive protein (CRP), and markers of oxidative stress were measured.

STUDY DESIGN

Two-arms open prospective randomized study.

Subjects

Healthy volunteers aged 20-50 years were recruited from the staff of the S.Giovanni Battista Hospital of Turin.

Inclusion criteria were: age 20-50 years, absence of known hyperglycemia, hypertension, cardiovascular disease, impaired renal function, liver disease, or any other systemic conditions, no use of any drug -estrogen included-, not being on a particular diet and/or vitamin or other nutrient supplementation

Exclusion criteria were: actual pregnancy, known hyperglycemia, hypertension, cardiovascular disease, impaired renal function, liver disease, or any other systemic conditions, use of any drug -estrogen included-, being on a particular diet and/or vitamin or other nutrient supplementation; history of renal calculi.

Randomization

After a full baseline evaluation of all included subjects, they were stratified according to:

  1. age,
  2. sex,
  3. smoking habits,
  4. body mass index (BMI),
  5. fasting blood levels of glucose, hs-CRP, vitamin C, and resistin.

The randomization procedure was automatically performed by a statistician, using a SAS program developed to minimize the differences between the two groups for all the stratifying variables.

Treatments

Subjects were randomly allocated, within each stratum, to receive either daily 2 g ascorbic acid (Cebionâ 1000 per 2/die) supplementation or no supplementation for 14 days. The final distribution was: 40 subjects on vitamin C supplementation (experimental group) and 40 not supplemented (control group). These dosages were demonstrated to be safe also for prolonged treatments10

Endpoints

Main endpoints: mean resistin serum level reduction, after vitamin C treatment, of at least 0.50 standardized units.

Secondary endpoints: the within- and between-group variations in the other inflammatory and oxidative variables measured.

Sample size

On the basis of our previous data21, a sample of at least 34 subjects per group was required to detect a standardized difference of 0.5 DS resistin reduction in the experimental group, with a statistical power of 80% and two-tailed 0.05 a-value. Taking into account the limitations of these assumptions and the possibility of missing some individuals, the total sample size was increased to 40 subjects per group.

Statistics

The t-Student test for paired data will be used to investigate variations in the concentrations of several blood variables in the experimental group and in the control group. To assess whether these changes are different between the two groups, t-tests for independent samples, assuming either equal or unequal variances, will be performed.

Measurements

All the subjects will be submitted in the morning, at fasting, before and after the treatment, to measurements of weight, waist circumference, blood pressure, and to determinations of serum glucose, total cholesterol, HDL-cholesterol, triglyceride, insulin, high sensitivity C reactive protein (hs-CRP), vitamin A, C, E, oxidized and reduced glutathione, NT, and resistin levels. Data about smoking habits, physical activity and mean daily nutrient intakes will be collected, respectively, by an interview, and a validated 3-day food record.

REFERENCES

  1. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 18: 307-312
  2. Steppan CM, Brown EJ, Wright CM, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98: 502-506
  3. Hotamisligil GS. The irresistible biology of resistin. J Clin Invest 2003; 111: 173-174
  4. Savage DB, Sewter CP, Klens ES, et al. Resistin/FIZZ3 expression in relation to obesity and peroxisome proliferator-activated receptor g action in humans. Diabetes 2001; 50: 2199-2202
  5. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002; 10: 1-5
  6. Gomez-Ambrosi J, Frühbeck G. Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med 2001; 135: 306-307
  7. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003; 52: 1611-1618
  8. Felipe F, Bonet ML, Ribot J, Palou A. Modulation of resistin expression by retinoic acid and vitamin A status. Diabetes 2004; 53: 882-889
  9. Bo S, Gambino R, Pagani A, et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes 2005;29:1315-1320
  10. Tousoulis D, Antoniades C, Tentolouris C, Tsioufis C, Toutouza P, Stefanadis C. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis 2003; 170: 261-267.

Study Type

Interventional

Enrollment

80

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Turin, Italy, 10126
        • Department of Internal Medicine, University of Turin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age 20-50 years
  • absence of known hyperglycemia, hypertension, cardiovascular disease, impaired renal function, liver disease, or any other systemic conditions no use of any drug, estrogen included
  • not being on a particular diet and/or vitamin or other nutrient supplementation

Exclusion Criteria:

  • actual pregnancy
  • known hyperglycemia, hypertension, cardiovascular disease, impaired renal function, liver disease, or any other systemic conditions
  • use of any drug, estrogen included
  • being on a particular diet, vitamin or other nutrient supplementation
  • history of renal calculi.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Mean resistin serum level reduction, after vitamin C treatment, of at least 0.50 standardized units.

Secondary Outcome Measures

Outcome Measure
The within- and between-group variations in the other inflammatory and oxidative variables measured.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Turin, Italy

Investigators

  • Principal Investigator: Gianfranco Pagano, MD, University of Turin, Italy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2005

Study Completion

November 1, 2005

Study Registration Dates

First Submitted

October 10, 2006

First Submitted That Met QC Criteria

October 10, 2006

First Posted (Estimate)

October 12, 2006

Study Record Updates

Last Update Posted (Estimate)

October 12, 2006

Last Update Submitted That Met QC Criteria

October 10, 2006

Last Verified

October 1, 2006

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2005-002368-27

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Diseases

Clinical Trials on Vitamin C

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe